var data={"title":"Becaplermin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Becaplermin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5705?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=becaplermin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Becaplermin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6131564\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Malignancy: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">An increased rate of mortality secondary to malignancy was observed in patients treated with 3 or more tubes of becaplermin in a postmarketing retrospective cohort study. Becaplermin should only be used when the benefits can be expected to outweigh the risks. Becaplermin should be used with caution in patients with known malignancy.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139209\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Regranex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139219\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Growth Factor, Platelet-derived;</li>\n      <li>\n        Topical Skin Product</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139211\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Diabetic ulcers (lower extremity):</b> Topical: Apply appropriate amount of gel once daily with a cotton swab, tongue depressor, or similar tool, as a coating over the ulcer. The amount of becaplermin to be applied will vary depending on the size of the ulcer area.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Note:</b> If the ulcer does not decrease in size by ~30% after 10 weeks of treatment or complete healing has not occurred in 20 weeks, continued treatment with becaplermin gel should be reassessed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Estimation of gel requirement:</i> To calculate the length of gel applied to the ulcer, measure the greatest length of the ulcer by the greatest width of the ulcer. Tube size and unit of measure will determine the formula used in the calculation. Recalculate amount of gel needed every 1 to 2 weeks, depending on the rate of change in ulcer area. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Centimeters:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">15 g tube: [ulcer length (cm) x width (cm)] divided by 4 = length of gel (cm)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">2 g tube: [ulcer length (cm) x width (cm)] divided by 2 = length of gel (cm)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Inches:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">15 g tube: [length (in) x width (in)] x 0.6 = length of gel (in)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">2 g tube: [length (in) x width (in)] x 1.3 = length of gel (in)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28185912\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Diabetic ulcers (lower extremity):</b> Adolescents &ge;16 years: Refer to adult dosing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139212\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28185913\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28185914\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139199\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gel, External: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Regranex: 0.01% (15 g) [contains metacresol, methylparaben, propylparaben]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139186\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6131603\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">For topical use; not for oral, ophthalmic, or intravaginal use. Squeeze appropriate amount of gel onto clean measuring surface (eg, wax paper), spread onto entire ulcer area in a thin, continuous layer ~<sup>1</sup>/<sub>16</sub> inch thick. Cover with saline moistened dressing; leave dressing in place ~12 hours. After 12 hours, remove dressing, rinse with saline or water to remove residual becaplermin gel and cover with saline moistened dressing (without becaplermin gel) for remainder of the day. Continue use once daily until ulcer is completely healed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139200\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Diabetic ulcers:</b> Adjunctive treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Limitations of use: Efficacy has not been established for pressure and venous stasis ulcers; has not been evaluated for diabetic neuropathic ulcers that do not extend through the dermis into subcutaneous tissue (stage I or II, International Association of Enterostomal Therapy [IAET] staging classification) or ischemic diabetic ulcers.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139225\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Regranex may be confused with Granulex, Repronex</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139193\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%: Dermatologic: Erythematous rash (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Connective tissue disorder (excessive granulation tissue), dermal ulcer (with or without tunneling), erythema (with purulent discharge), local pain</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139203\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Known neoplasm(s) at the site(s) of application</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139190\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Application site reactions: Sensitization or irritation of skin may occur; may be due to parabens or m-cresol. Interruption or discontinuation of treatment should be considered; further evaluation (eg, patch testing) may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Malignancy: <b>[U.S. Boxed Warning]: An increased rate of mortality secondary to malignancies was observed in a postmarketing retrospective cohort study of patients treated with &ge;3 tubes of becaplermin. Becaplermin should only be used when the benefits can be expected to outweigh the risks. Use with caution in patients with known malignancy.</b> Malignancies of varying types have been reported; all were remote from the becaplermin treatment site.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: For external use only; do not use in wounds that close by primary intention. Effects on exposed joints, tendons, ligaments and bone have not been established. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298816\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6218246\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8596&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139195\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6131565\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16257699\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if becaplermin is excreted in breast milk. The manufacturer recommends that caution be exercised when administering becaplermin to nursing women. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139197\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Ulcer volume (pressure ulcers); wound area; evidence of closure; drainage (diabetic ulcers); signs/symptoms of toxicity (erythema, local infections)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139189\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Recombinant B-isoform homodimer of human platelet-derived growth factor (rPDGF-BB) which enhances formation of new granulation tissue, induces fibroblast proliferation and differentiation to promote wound healing; also promotes angiogenesis. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139204\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Regranex External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.01% (15 g): $1,278.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139205\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Becaplex (LB);</li>\n      <li>Regranex (AT, BB, BE, BG, CH, DE, DK, EE, ES, FI, FR, GB, GR, HN, HU, IE, IL, IT, KR, MT, MX, NL, NO, PL, PT, RO, RU, SE, SK, TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Cohen V, Jellinek SP, Teperikidis L, et al, &ldquo;Room-Temperature Storage of Medications Labeled for Refrigeration,&rdquo; <i>Am J Health-Syst Pharm</i>, 2007, 64(16):1711-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/becaplermin-drug-information/abstract-text/17687059/pubmed\" target=\"_blank\" id=\"17687059\">17687059</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Regranex (becaplermin) [prescribing information]. Fort Worth, TX: Smith &amp; Nephew Biotherapeutics; February 2017.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8596 Version 97.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F6131564\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F139209\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F139219\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F139211\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F28185912\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F139212\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F28185913\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F28185914\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F139199\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F139186\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F6131603\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F139200\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F139225\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F139193\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F139203\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F139190\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298816\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6218246\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F139195\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6131565\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F16257699\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F139197\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F139189\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F139204\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F139205\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8596|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=becaplermin-patient-drug-information\" class=\"drug drug_patient\">Becaplermin: Patient drug information</a></li></ul></div></div>","javascript":null}